
|Videos|July 29, 2013
Potential Cost Savings of Biosimilars
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
Advertisement
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
For more videos featuring Debbie Stern, please click on our
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
2
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
3
Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























